Skip to main content
Joel Gallant, MD, Infectious Disease, Foster City, CA

JoelEmanuelGallantMDMPH

Infectious Disease Foster City, CA

HIV/AIDS Medicine

Executive Director, HIV Global Medical Affairs

Dr. Gallant is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gallant's full profile

Already have an account?

Summary

  • I am board certified in internal medicine and infectious diseases, with expertise in the prevention and treatment of HIV infection. I am now at Gilead Sciences, working primarily on HIV therapy.

Education & Training

  • Johns Hopkins School of Hygiene and Public Health
    Johns Hopkins School of Hygiene and Public HealthMPH, Internaional Health, John C. Hume Masters in Public Health Award, Delta Omega Public Health Honor Society, 1989 - 1990
  • Yale-New Haven Hospital
    Yale-New Haven HospitalResidency, Internal Medicine, 1985 - 1988
  • University of California (San Francisco) School of Medicine
    University of California (San Francisco) School of MedicineClass of 1985

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2019 - 2023
  • NM State Medical License
    NM State Medical License 2012 - 2019
  • MD State Medical License
    MD State Medical License 1989 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com
  • HIV Clinical Educator Award HIV Medicine Association and Infectious Disease Society of America

Publications & Presentations

PubMed

Lectures

  • 23rd Annual Clinical Care of the Patient with HIV Infection 
    The Johns Hopkins University School of Medicine, Baltimore, Maryland - 3/18/2013

Other

Press Mentions

  • Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
    Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIVJuly 24th, 2017
  • HIV Treatment Good and Getting Better
    HIV Treatment Good and Getting BetterDecember 1st, 2016
  • Gilead Announces Results from First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada
    Gilead Announces Results from First Study to Evaluate Switching to F/TAF-Based Regimens from TruvadaFebruary 26th, 2016
  • Join now to see all

Grant Support

  • ACTG A5202National Center For Research Resources2006–2007
  • ACTG A5142National Center For Research Resources2004–2007
  • AIDS Related Nonhodgkin'S Lymphoma/Kaposi'S Sarcoma And Other MalignanciesNational Center For Research Resources1998–2002
  • Phase II Safety, Plasma Pharmacokinetics &AntiretroviralNational Center For Research Resources1999

Professional Memberships

Other Languages

  • Spanish